A nationwide survey by the National Vaccine Institute (NVI) has revealed overwhelming public confidence in immunisation, alongside robust support for Ghana’s upcoming local vaccine manufacturing initiative slated for launch in 2027.
A comprehensive study, analysing 13,905 valid responses across all 16 regions and 55 districts, found that 89.7% of Ghanaians trust vaccines, while 94.2% view securing vaccine availability as a collective national responsibility.
Crucially, 71.3% of respondents expressed willingness to accept and use vaccines manufactured domestically once production begins.
The Awareness Gap and Regional Disparities
Despite high baseline trust, researchers flagged a severe deficit in public awareness regarding the country’s manufacturing roadmap.
Only 14.3% of those surveyed knew that Ghana is actively building local vaccine production capacity ahead of the 2027 rollout. The data also exposed surprising geographic variations in vaccine sentiment.
Urbanised hubs—specifically the Greater Accra, Central, and Ashanti regions—recorded lower vaccine acceptance levels despite having greater access to information.
Conversely, rural communities in northern Ghana and the Oti Region demonstrated significantly stronger trust and acceptance.
Furthermore, the public cited structural challenges that could hinder vaccine uptake, including out-of-pocket costs, long travel distances to health centres, and fragile rural cold-chain storage and transportation networks.
Trust in Local Scientific Capacity
A powerful driver of potential acceptance is national pride. Respondents noted that seeing Ghanaian scientists and local factories leading the production process would substantially boost their confidence in the final products.
The survey also highlighted deep institutional trust: 87.8% of respondents trust the doctors and nurses administering vaccines, while public confidence remains high in both the Ghana Health Service (GHS) and the Food and Drugs Authority (FDA).
Strategic Next Steps
Reacting to the findings, NVI Chief Executive Officer, Dr Sodzi Sodzi-Tettey, emphasised that while Ghana possesses a strong foundation of vaccine confidence, long-term success hinges on aggressive education.
“Success will depend on bridging the awareness and trust gap regarding locally manufactured vaccines,” Dr Sodzi-Tettey stated.
He called for targeted policy interventions and communication strategies to counter misinformation, dismantle cost barriers, and resolve regional disparities.
In response, the NVI is preparing a nationwide awareness campaign. The rollout will unify efforts across government agencies, healthcare professionals, civil society organisations, community leaders, the private sector, and the media to foster public ownership of the project.
Broader Continental Alignment
This shift toward vaccine self-sufficiency arrives at a critical juncture for Ghana’s pharmaceutical sector as it looks to fortify national health security, spur industrial growth, and drive scientific innovation.
On a continental scale, Ghana’s initiative aligns directly with the African Union’s Partnerships for African Vaccine Manufacturing (PAVM) vision, which aims to manufacture at least 60% of Africa’s required vaccines locally by 2040.